Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-400 + fluorouracil + folinic acid + bevacizumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ABBV-400 + fluorouracil + folinic acid + bevacizumab is a combination regimen being studied in advanced and metastatic colorectal cancer, particularly in patients previously treated for their disease. **ABBV-400** (telisotuzumab adizutecan) is an antibody-drug conjugate that targets the c-Met (MET) protein, which is often overexpressed in solid tumors. ABBV-400 uses a c-Met–binding antibody linked to a topoisomerase 1 inhibitor payload. **Fluorouracil** is a pyrimidine analog antimetabolite that interferes with DNA synthesis. **Folinic acid** (leucovorin) potentiates the anticancer effect of fluorouracil by stabilizing the fluorouracil–thymidylate synthase complex. **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis. This combination is evaluated in clinical trials for efficacy and safety in metastatic colorectal cancer, leveraging multiple mechanisms: targeted killing of c-Met–expressing cells, inhibition of angiogenesis, and cytotoxic effects on tumor DNA synthesis[2][5].
- Other names
- telisotuzumab adizutecan + fluorouracil + folinic acid + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)MET (Mesenchymal-epithelial transition factor receptor)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on ABBV-400 + fluorouracil + folinic acid + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-400 + fluorouracil + folinic acid + bevacizumab.